384 related articles for article (PubMed ID: 25109825)
1. Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study.
Gokhale M; Buse JB; Gray CL; Pate V; Marquis MA; Stürmer T
Diabetes Obes Metab; 2014 Dec; 16(12):1247-56. PubMed ID: 25109825
[TBL] [Abstract][Full Text] [Related]
2. No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives.
Gokhale M; Buse JB; Jonsson Funk M; Lund J; Pate V; Simpson RJ; Stürmer T
Diabetes Obes Metab; 2017 Jul; 19(7):970-978. PubMed ID: 28195389
[TBL] [Abstract][Full Text] [Related]
3. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.
Garry EM; Buse JB; Lund JL; Pate V; Stürmer T
Diabetes Obes Metab; 2018 Jan; 20(1):129-140. PubMed ID: 28661561
[TBL] [Abstract][Full Text] [Related]
4. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults.
Wang T; Yang JY; Buse JB; Pate V; Tang H; Barnes EL; Sandler RS; Stürmer T
Diabetes Care; 2019 Nov; 42(11):2065-2074. PubMed ID: 31471377
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
Farr AM; Sheehan JJ; Curkendall SM; Smith DM; Johnston SS; Kalsekar I
Adv Ther; 2014 Dec; 31(12):1287-305. PubMed ID: 25504156
[TBL] [Abstract][Full Text] [Related]
8. Effect of dipeptidyl peptidase IV inhibitors, thiazolidinedione, and sulfonylurea on osteoporosis in patients with type 2 diabetes: population-based cohort study.
Yang BR; Cha SH; Lee KE; Kim JW; Lee J; Shin KH
Osteoporos Int; 2021 Sep; 32(9):1705-1712. PubMed ID: 33594487
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
10. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
11. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.
Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Juurlink DN; Targownik LE; Turin TC; Paterson JM; Ernst P;
BMJ; 2016 Feb; 352():i581. PubMed ID: 26888382
[TBL] [Abstract][Full Text] [Related]
12. Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic.
Kannan S; Pantalone KM; Matsuda S; Wells BJ; Karafa M; Zimmerman RS
J Diabetes; 2016 Mar; 8(2):279-85. PubMed ID: 25929426
[TBL] [Abstract][Full Text] [Related]
13. Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults.
Wang T; Hong JL; Gower EW; Pate V; Garg S; Buse JB; Stürmer T
Diabetes Care; 2018 Sep; 41(9):1998-2009. PubMed ID: 30012674
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea.
Lee H; Chung HJ; Pawar A; Patorno E; Kim DH
JAMA Dermatol; 2020 Oct; 156(10):1107-1114. PubMed ID: 32697283
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality.
Morgan CL; Mukherjee J; Jenkins-Jones S; Holden SE; Currie CJ
Diabetes Obes Metab; 2014 Oct; 16(10):977-83. PubMed ID: 24762119
[TBL] [Abstract][Full Text] [Related]
16. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study.
Seong JM; Choi NK; Shin JY; Chang Y; Kim YJ; Lee J; Kim JY; Park BJ
PLoS One; 2015; 10(5):e0124287. PubMed ID: 25992614
[TBL] [Abstract][Full Text] [Related]
17. Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study.
Alkabbani W; Zongo A; Minhas-Sandhu JK; Eurich DT; Shah BR; Alsabbagh MW; Gamble JM
Can J Diabetes; 2022 Jun; 46(4):392-403.e13. PubMed ID: 35513988
[TBL] [Abstract][Full Text] [Related]
18. Use of dipeptidyl peptidase-4 inhibitors and the risk of arthralgia: Population-based cohort and nested case-control studies.
Wang CY; Fu SH; Yang RS; Hsiao FY
Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):500-506. PubMed ID: 30724413
[TBL] [Abstract][Full Text] [Related]
19. Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study.
Lee SJ; Ha KH; Lee JH; Lee H; Kim DJ; Kim HC
PLoS One; 2019; 14(2):e0211959. PubMed ID: 30742667
[TBL] [Abstract][Full Text] [Related]
20. Risk of genital and urinary tract infections associated with SGLT-2 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea.
Yang H; Choi E; Park E; Na E; Chung SY; Kim B; Han SY
Pharmacol Res Perspect; 2022 Feb; 10(1):e00910. PubMed ID: 35005849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
